Global CD30 (TNFRSF8) Antibody Production, Demand and Key Producers, 2022-2028
CD30 (TNFRSF8) Antibody is an unconjugated antibody to CD30.
This report studies the global CD30 (TNFRSF8) Antibody production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for CD30 (TNFRSF8) Antibody, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of CD30 (TNFRSF8) Antibody that contribute to its increasing demand across many markets.
The global CD30 (TNFRSF8) Antibody market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global CD30 (TNFRSF8) Antibody total production and demand, 2017-2028, (K Units)
Global CD30 (TNFRSF8) Antibody total production value, 2017-2028, (USD Million)
Global CD30 (TNFRSF8) Antibody production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global CD30 (TNFRSF8) Antibody consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: CD30 (TNFRSF8) Antibody domestic production, consumption, key domestic manufacturers and share
Global CD30 (TNFRSF8) Antibody production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global CD30 (TNFRSF8) Antibody production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global CD30 (TNFRSF8) Antibody production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global CD30 (TNFRSF8) Antibody market based on the following parameters – headquarters, production locations, products portfolio, CD30 (TNFRSF8) Antibody revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World CD30 (TNFRSF8) Antibody market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global CD30 (TNFRSF8) Antibody Market, By Region:
1. How big is the global CD30 (TNFRSF8) Antibody market?
2. What is the demand of the global CD30 (TNFRSF8) Antibody market?
3. What is the year over year growth of the global CD30 (TNFRSF8) Antibody market?
4. What is the production and production value of the global CD30 (TNFRSF8) Antibody market?
5. Who are the key producers in the global CD30 (TNFRSF8) Antibody market?
6. What are the growth factors driving the market demand?
This report studies the global CD30 (TNFRSF8) Antibody production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for CD30 (TNFRSF8) Antibody, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of CD30 (TNFRSF8) Antibody that contribute to its increasing demand across many markets.
The global CD30 (TNFRSF8) Antibody market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global CD30 (TNFRSF8) Antibody total production and demand, 2017-2028, (K Units)
Global CD30 (TNFRSF8) Antibody total production value, 2017-2028, (USD Million)
Global CD30 (TNFRSF8) Antibody production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global CD30 (TNFRSF8) Antibody consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: CD30 (TNFRSF8) Antibody domestic production, consumption, key domestic manufacturers and share
Global CD30 (TNFRSF8) Antibody production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global CD30 (TNFRSF8) Antibody production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global CD30 (TNFRSF8) Antibody production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global CD30 (TNFRSF8) Antibody market based on the following parameters – headquarters, production locations, products portfolio, CD30 (TNFRSF8) Antibody revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World CD30 (TNFRSF8) Antibody market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global CD30 (TNFRSF8) Antibody Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Monoclonal Antibody
- Polyclonal Antibody
- Flow Cytometry
- ELISA
- Western Blot
- Immunofluorescence
- Other
- Sino Biological, Inc.
- Bio-Techne
- Thermo Fisher Scientific (China) Co., Ltd.
- Boster Biological Technology
- MyBiosource, Inc.
- Abeomics Inc.
- Abbexa
- Cell Signaling Technology, Inc.
- Creative Diagnostics
- OriGene Technologies, Inc.
- Merck
- Cayman Chemical
- CUSABIO
- Biotium
- BioLegend
- Abcepta
- ProSci Incorporated
1. How big is the global CD30 (TNFRSF8) Antibody market?
2. What is the demand of the global CD30 (TNFRSF8) Antibody market?
3. What is the year over year growth of the global CD30 (TNFRSF8) Antibody market?
4. What is the production and production value of the global CD30 (TNFRSF8) Antibody market?
5. Who are the key producers in the global CD30 (TNFRSF8) Antibody market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 CD30 (TNFRSF8) Antibody Introduction
1.2 World CD30 (TNFRSF8) Antibody Supply & Forecast
1.2.1 World CD30 (TNFRSF8) Antibody Production Value (2017 & 2021 & 2028)
1.2.2 World CD30 (TNFRSF8) Antibody Production (2017-2028)
1.2.3 World CD30 (TNFRSF8) Antibody Pricing Trends (2017-2028)
1.3 World CD30 (TNFRSF8) Antibody Production by Region
1.3.1 World CD30 (TNFRSF8) Antibody Production Value by Region (2017-2028)
1.3.2 World CD30 (TNFRSF8) Antibody Production by Region (2017-2028)
1.3.3 World CD30 (TNFRSF8) Antibody Average Price by Region (2017-2028)
1.3.4 North America CD30 (TNFRSF8) Antibody Production (2017-2028)
1.3.5 Europe CD30 (TNFRSF8) Antibody Production (2017-2028)
1.3.6 China CD30 (TNFRSF8) Antibody Production (2017-2028)
1.3.7 Japan CD30 (TNFRSF8) Antibody Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 CD30 (TNFRSF8) Antibody Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 CD30 (TNFRSF8) Antibody Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World CD30 (TNFRSF8) Antibody Demand (2017-2028)
2.2 World CD30 (TNFRSF8) Antibody Consumption by Region
2.2.1 World CD30 (TNFRSF8) Antibody Consumption by Region (2017-2022)
2.2.2 World CD30 (TNFRSF8) Antibody Consumption Forecast by Region (2023-2028)
2.3 United States CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.4 China CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.5 Europe CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.6 Japan CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.7 South Korea CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.8 ASEAN CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.9 India CD30 (TNFRSF8) Antibody Consumption (2017-2028)
3 WORLD CD30 (TNFRSF8) ANTIBODY MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World CD30 (TNFRSF8) Antibody Production Value by Manufacturer (2017-2022)
3.2 World CD30 (TNFRSF8) Antibody Production by Manufacturer (2017-2022)
3.3 World CD30 (TNFRSF8) Antibody Average Price by Manufacturer (2017-2022)
3.4 CD30 (TNFRSF8) Antibody Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global CD30 (TNFRSF8) Antibody Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for CD30 (TNFRSF8) Antibody in 2021
3.5.3 Global Concentration Ratios (CR8) for CD30 (TNFRSF8) Antibody in 2021
3.6 CD30 (TNFRSF8) Antibody Market: Overall Company Footprint Analysis
3.6.1 CD30 (TNFRSF8) Antibody Market: Region Footprint
3.6.2 CD30 (TNFRSF8) Antibody Market: Company Product Type Footprint
3.6.3 CD30 (TNFRSF8) Antibody Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: CD30 (TNFRSF8) Antibody Production Value Comparison
4.1.1 United States VS China: CD30 (TNFRSF8) Antibody Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: CD30 (TNFRSF8) Antibody Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: CD30 (TNFRSF8) Antibody Production Comparison
4.2.1 United States VS China: CD30 (TNFRSF8) Antibody Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: CD30 (TNFRSF8) Antibody Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: CD30 (TNFRSF8) Antibody Consumption Comparison
4.3.1 United States VS China: CD30 (TNFRSF8) Antibody Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: CD30 (TNFRSF8) Antibody Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States CD30 (TNFRSF8) Antibody Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of CD30 (TNFRSF8) Antibody in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022)
4.5 China CD30 (TNFRSF8) Antibody Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of CD30 (TNFRSF8) Antibody in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World CD30 (TNFRSF8) Antibody Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of CD30 (TNFRSF8) Antibody in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World CD30 (TNFRSF8) Antibody Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Monoclonal Antibody
5.2.2 Polyclonal Antibody
5.3 Market Segment by Type
5.3.1 World CD30 (TNFRSF8) Antibody Production by Type (2017-2028)
5.3.2 World CD30 (TNFRSF8) Antibody Production Value by Type (2017-2028)
5.3.3 World CD30 (TNFRSF8) Antibody Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World CD30 (TNFRSF8) Antibody Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 Flow Cytometry
6.2.2 ELISA
6.2.3 Western Blot
6.2.4 Immunofluorescence
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World CD30 (TNFRSF8) Antibody Production by Application (2017-2028)
6.3.2 World CD30 (TNFRSF8) Antibody Production Value by Application (2017-2028)
6.3.3 World CD30 (TNFRSF8) Antibody Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 Sino Biological, Inc.
7.1.1 Sino Biological, Inc. Details
7.1.2 Sino Biological, Inc. Major Business
7.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.1.4 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 Sino Biological, Inc. Recent Developments/Updates
7.1.6 Sino Biological, Inc. Competitive Strengths & Weaknesses
7.2 Bio-Techne
7.2.1 Bio-Techne Details
7.2.2 Bio-Techne Major Business
7.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Product and Services
7.2.4 Bio-Techne CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Bio-Techne Recent Developments/Updates
7.2.6 Bio-Techne Competitive Strengths & Weaknesses
7.3 Thermo Fisher Scientific (China) Co., Ltd.
7.3.1 Thermo Fisher Scientific (China) Co., Ltd. Details
7.3.2 Thermo Fisher Scientific (China) Co., Ltd. Major Business
7.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product and Services
7.3.4 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
7.3.6 Thermo Fisher Scientific (China) Co., Ltd. Competitive Strengths & Weaknesses
7.4 Boster Biological Technology
7.4.1 Boster Biological Technology Details
7.4.2 Boster Biological Technology Major Business
7.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product and Services
7.4.4 Boster Biological Technology CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Boster Biological Technology Recent Developments/Updates
7.4.6 Boster Biological Technology Competitive Strengths & Weaknesses
7.5 MyBiosource, Inc.
7.5.1 MyBiosource, Inc. Details
7.5.2 MyBiosource, Inc. Major Business
7.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.5.4 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 MyBiosource, Inc. Recent Developments/Updates
7.5.6 MyBiosource, Inc. Competitive Strengths & Weaknesses
7.6 Abeomics Inc.
7.6.1 Abeomics Inc. Details
7.6.2 Abeomics Inc. Major Business
7.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product and Services
7.6.4 Abeomics Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 Abeomics Inc. Recent Developments/Updates
7.6.6 Abeomics Inc. Competitive Strengths & Weaknesses
7.7 Abbexa
7.7.1 Abbexa Details
7.7.2 Abbexa Major Business
7.7.3 Abbexa CD30 (TNFRSF8) Antibody Product and Services
7.7.4 Abbexa CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Abbexa Recent Developments/Updates
7.7.6 Abbexa Competitive Strengths & Weaknesses
7.8 Cell Signaling Technology, Inc.
7.8.1 Cell Signaling Technology, Inc. Details
7.8.2 Cell Signaling Technology, Inc. Major Business
7.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.8.4 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 Cell Signaling Technology, Inc. Recent Developments/Updates
7.8.6 Cell Signaling Technology, Inc. Competitive Strengths & Weaknesses
7.9 Creative Diagnostics
7.9.1 Creative Diagnostics Details
7.9.2 Creative Diagnostics Major Business
7.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product and Services
7.9.4 Creative Diagnostics CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Creative Diagnostics Recent Developments/Updates
7.9.6 Creative Diagnostics Competitive Strengths & Weaknesses
7.10 OriGene Technologies, Inc.
7.10.1 OriGene Technologies, Inc. Details
7.10.2 OriGene Technologies, Inc. Major Business
7.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.10.4 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 OriGene Technologies, Inc. Recent Developments/Updates
7.10.6 OriGene Technologies, Inc. Competitive Strengths & Weaknesses
7.11 Merck
7.11.1 Merck Details
7.11.2 Merck Major Business
7.11.3 Merck CD30 (TNFRSF8) Antibody Product and Services
7.11.4 Merck CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.11.5 Merck Recent Developments/Updates
7.11.6 Merck Competitive Strengths & Weaknesses
7.12 Cayman Chemical
7.12.1 Cayman Chemical Details
7.12.2 Cayman Chemical Major Business
7.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product and Services
7.12.4 Cayman Chemical CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.12.5 Cayman Chemical Recent Developments/Updates
7.12.6 Cayman Chemical Competitive Strengths & Weaknesses
7.13 CUSABIO
7.13.1 CUSABIO Details
7.13.2 CUSABIO Major Business
7.13.3 CUSABIO CD30 (TNFRSF8) Antibody Product and Services
7.13.4 CUSABIO CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.13.5 CUSABIO Recent Developments/Updates
7.13.6 CUSABIO Competitive Strengths & Weaknesses
7.14 Biotium
7.14.1 Biotium Details
7.14.2 Biotium Major Business
7.14.3 Biotium CD30 (TNFRSF8) Antibody Product and Services
7.14.4 Biotium CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.14.5 Biotium Recent Developments/Updates
7.14.6 Biotium Competitive Strengths & Weaknesses
7.15 BioLegend
7.15.1 BioLegend Details
7.15.2 BioLegend Major Business
7.15.3 BioLegend CD30 (TNFRSF8) Antibody Product and Services
7.15.4 BioLegend CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.15.5 BioLegend Recent Developments/Updates
7.15.6 BioLegend Competitive Strengths & Weaknesses
7.16 Abcepta
7.16.1 Abcepta Details
7.16.2 Abcepta Major Business
7.16.3 Abcepta CD30 (TNFRSF8) Antibody Product and Services
7.16.4 Abcepta CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.16.5 Abcepta Recent Developments/Updates
7.16.6 Abcepta Competitive Strengths & Weaknesses
7.17 ProSci Incorporated
7.17.1 ProSci Incorporated Details
7.17.2 ProSci Incorporated Major Business
7.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product and Services
7.17.4 ProSci Incorporated CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.17.5 ProSci Incorporated Recent Developments/Updates
7.17.6 ProSci Incorporated Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of CD30 (TNFRSF8) Antibody and Key Manufacturers
8.2 CD30 (TNFRSF8) Antibody Manufacturing Costs
8.3 CD30 (TNFRSF8) Antibody Production Process
8.4 CD30 (TNFRSF8) Antibody Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for CD30 (TNFRSF8) Antibody Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 CD30 (TNFRSF8) Antibody Typical Distributors
9.3 CD30 (TNFRSF8) Antibody Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 CD30 (TNFRSF8) Antibody Introduction
1.2 World CD30 (TNFRSF8) Antibody Supply & Forecast
1.2.1 World CD30 (TNFRSF8) Antibody Production Value (2017 & 2021 & 2028)
1.2.2 World CD30 (TNFRSF8) Antibody Production (2017-2028)
1.2.3 World CD30 (TNFRSF8) Antibody Pricing Trends (2017-2028)
1.3 World CD30 (TNFRSF8) Antibody Production by Region
1.3.1 World CD30 (TNFRSF8) Antibody Production Value by Region (2017-2028)
1.3.2 World CD30 (TNFRSF8) Antibody Production by Region (2017-2028)
1.3.3 World CD30 (TNFRSF8) Antibody Average Price by Region (2017-2028)
1.3.4 North America CD30 (TNFRSF8) Antibody Production (2017-2028)
1.3.5 Europe CD30 (TNFRSF8) Antibody Production (2017-2028)
1.3.6 China CD30 (TNFRSF8) Antibody Production (2017-2028)
1.3.7 Japan CD30 (TNFRSF8) Antibody Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 CD30 (TNFRSF8) Antibody Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 CD30 (TNFRSF8) Antibody Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World CD30 (TNFRSF8) Antibody Demand (2017-2028)
2.2 World CD30 (TNFRSF8) Antibody Consumption by Region
2.2.1 World CD30 (TNFRSF8) Antibody Consumption by Region (2017-2022)
2.2.2 World CD30 (TNFRSF8) Antibody Consumption Forecast by Region (2023-2028)
2.3 United States CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.4 China CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.5 Europe CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.6 Japan CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.7 South Korea CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.8 ASEAN CD30 (TNFRSF8) Antibody Consumption (2017-2028)
2.9 India CD30 (TNFRSF8) Antibody Consumption (2017-2028)
3 WORLD CD30 (TNFRSF8) ANTIBODY MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World CD30 (TNFRSF8) Antibody Production Value by Manufacturer (2017-2022)
3.2 World CD30 (TNFRSF8) Antibody Production by Manufacturer (2017-2022)
3.3 World CD30 (TNFRSF8) Antibody Average Price by Manufacturer (2017-2022)
3.4 CD30 (TNFRSF8) Antibody Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global CD30 (TNFRSF8) Antibody Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for CD30 (TNFRSF8) Antibody in 2021
3.5.3 Global Concentration Ratios (CR8) for CD30 (TNFRSF8) Antibody in 2021
3.6 CD30 (TNFRSF8) Antibody Market: Overall Company Footprint Analysis
3.6.1 CD30 (TNFRSF8) Antibody Market: Region Footprint
3.6.2 CD30 (TNFRSF8) Antibody Market: Company Product Type Footprint
3.6.3 CD30 (TNFRSF8) Antibody Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: CD30 (TNFRSF8) Antibody Production Value Comparison
4.1.1 United States VS China: CD30 (TNFRSF8) Antibody Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: CD30 (TNFRSF8) Antibody Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: CD30 (TNFRSF8) Antibody Production Comparison
4.2.1 United States VS China: CD30 (TNFRSF8) Antibody Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: CD30 (TNFRSF8) Antibody Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: CD30 (TNFRSF8) Antibody Consumption Comparison
4.3.1 United States VS China: CD30 (TNFRSF8) Antibody Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: CD30 (TNFRSF8) Antibody Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States CD30 (TNFRSF8) Antibody Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of CD30 (TNFRSF8) Antibody in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022)
4.5 China CD30 (TNFRSF8) Antibody Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of CD30 (TNFRSF8) Antibody in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World CD30 (TNFRSF8) Antibody Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of CD30 (TNFRSF8) Antibody in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World CD30 (TNFRSF8) Antibody Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Monoclonal Antibody
5.2.2 Polyclonal Antibody
5.3 Market Segment by Type
5.3.1 World CD30 (TNFRSF8) Antibody Production by Type (2017-2028)
5.3.2 World CD30 (TNFRSF8) Antibody Production Value by Type (2017-2028)
5.3.3 World CD30 (TNFRSF8) Antibody Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World CD30 (TNFRSF8) Antibody Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 Flow Cytometry
6.2.2 ELISA
6.2.3 Western Blot
6.2.4 Immunofluorescence
6.2.5 Other
6.3 Market Segment by Application
6.3.1 World CD30 (TNFRSF8) Antibody Production by Application (2017-2028)
6.3.2 World CD30 (TNFRSF8) Antibody Production Value by Application (2017-2028)
6.3.3 World CD30 (TNFRSF8) Antibody Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 Sino Biological, Inc.
7.1.1 Sino Biological, Inc. Details
7.1.2 Sino Biological, Inc. Major Business
7.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.1.4 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 Sino Biological, Inc. Recent Developments/Updates
7.1.6 Sino Biological, Inc. Competitive Strengths & Weaknesses
7.2 Bio-Techne
7.2.1 Bio-Techne Details
7.2.2 Bio-Techne Major Business
7.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Product and Services
7.2.4 Bio-Techne CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Bio-Techne Recent Developments/Updates
7.2.6 Bio-Techne Competitive Strengths & Weaknesses
7.3 Thermo Fisher Scientific (China) Co., Ltd.
7.3.1 Thermo Fisher Scientific (China) Co., Ltd. Details
7.3.2 Thermo Fisher Scientific (China) Co., Ltd. Major Business
7.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product and Services
7.3.4 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
7.3.6 Thermo Fisher Scientific (China) Co., Ltd. Competitive Strengths & Weaknesses
7.4 Boster Biological Technology
7.4.1 Boster Biological Technology Details
7.4.2 Boster Biological Technology Major Business
7.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Product and Services
7.4.4 Boster Biological Technology CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Boster Biological Technology Recent Developments/Updates
7.4.6 Boster Biological Technology Competitive Strengths & Weaknesses
7.5 MyBiosource, Inc.
7.5.1 MyBiosource, Inc. Details
7.5.2 MyBiosource, Inc. Major Business
7.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.5.4 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 MyBiosource, Inc. Recent Developments/Updates
7.5.6 MyBiosource, Inc. Competitive Strengths & Weaknesses
7.6 Abeomics Inc.
7.6.1 Abeomics Inc. Details
7.6.2 Abeomics Inc. Major Business
7.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Product and Services
7.6.4 Abeomics Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 Abeomics Inc. Recent Developments/Updates
7.6.6 Abeomics Inc. Competitive Strengths & Weaknesses
7.7 Abbexa
7.7.1 Abbexa Details
7.7.2 Abbexa Major Business
7.7.3 Abbexa CD30 (TNFRSF8) Antibody Product and Services
7.7.4 Abbexa CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Abbexa Recent Developments/Updates
7.7.6 Abbexa Competitive Strengths & Weaknesses
7.8 Cell Signaling Technology, Inc.
7.8.1 Cell Signaling Technology, Inc. Details
7.8.2 Cell Signaling Technology, Inc. Major Business
7.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.8.4 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 Cell Signaling Technology, Inc. Recent Developments/Updates
7.8.6 Cell Signaling Technology, Inc. Competitive Strengths & Weaknesses
7.9 Creative Diagnostics
7.9.1 Creative Diagnostics Details
7.9.2 Creative Diagnostics Major Business
7.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Product and Services
7.9.4 Creative Diagnostics CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Creative Diagnostics Recent Developments/Updates
7.9.6 Creative Diagnostics Competitive Strengths & Weaknesses
7.10 OriGene Technologies, Inc.
7.10.1 OriGene Technologies, Inc. Details
7.10.2 OriGene Technologies, Inc. Major Business
7.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product and Services
7.10.4 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 OriGene Technologies, Inc. Recent Developments/Updates
7.10.6 OriGene Technologies, Inc. Competitive Strengths & Weaknesses
7.11 Merck
7.11.1 Merck Details
7.11.2 Merck Major Business
7.11.3 Merck CD30 (TNFRSF8) Antibody Product and Services
7.11.4 Merck CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.11.5 Merck Recent Developments/Updates
7.11.6 Merck Competitive Strengths & Weaknesses
7.12 Cayman Chemical
7.12.1 Cayman Chemical Details
7.12.2 Cayman Chemical Major Business
7.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Product and Services
7.12.4 Cayman Chemical CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.12.5 Cayman Chemical Recent Developments/Updates
7.12.6 Cayman Chemical Competitive Strengths & Weaknesses
7.13 CUSABIO
7.13.1 CUSABIO Details
7.13.2 CUSABIO Major Business
7.13.3 CUSABIO CD30 (TNFRSF8) Antibody Product and Services
7.13.4 CUSABIO CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.13.5 CUSABIO Recent Developments/Updates
7.13.6 CUSABIO Competitive Strengths & Weaknesses
7.14 Biotium
7.14.1 Biotium Details
7.14.2 Biotium Major Business
7.14.3 Biotium CD30 (TNFRSF8) Antibody Product and Services
7.14.4 Biotium CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.14.5 Biotium Recent Developments/Updates
7.14.6 Biotium Competitive Strengths & Weaknesses
7.15 BioLegend
7.15.1 BioLegend Details
7.15.2 BioLegend Major Business
7.15.3 BioLegend CD30 (TNFRSF8) Antibody Product and Services
7.15.4 BioLegend CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.15.5 BioLegend Recent Developments/Updates
7.15.6 BioLegend Competitive Strengths & Weaknesses
7.16 Abcepta
7.16.1 Abcepta Details
7.16.2 Abcepta Major Business
7.16.3 Abcepta CD30 (TNFRSF8) Antibody Product and Services
7.16.4 Abcepta CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.16.5 Abcepta Recent Developments/Updates
7.16.6 Abcepta Competitive Strengths & Weaknesses
7.17 ProSci Incorporated
7.17.1 ProSci Incorporated Details
7.17.2 ProSci Incorporated Major Business
7.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Product and Services
7.17.4 ProSci Incorporated CD30 (TNFRSF8) Antibody Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.17.5 ProSci Incorporated Recent Developments/Updates
7.17.6 ProSci Incorporated Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of CD30 (TNFRSF8) Antibody and Key Manufacturers
8.2 CD30 (TNFRSF8) Antibody Manufacturing Costs
8.3 CD30 (TNFRSF8) Antibody Production Process
8.4 CD30 (TNFRSF8) Antibody Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for CD30 (TNFRSF8) Antibody Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 CD30 (TNFRSF8) Antibody Typical Distributors
9.3 CD30 (TNFRSF8) Antibody Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World CD30 (TNFRSF8) Antibody Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World CD30 (TNFRSF8) Antibody Production Value by Region (2017-2022) & (USD Million)
Table 3. World CD30 (TNFRSF8) Antibody Production Value by Region (2023-2028) & (USD Million)
Table 4. World CD30 (TNFRSF8) Antibody Production Value Market Share by Region (2017-2022)
Table 5. World CD30 (TNFRSF8) Antibody Production Value Market Share by Region (2023-2028)
Table 6. World CD30 (TNFRSF8) Antibody Production by Region (2017-2022) & (K Units)
Table 7. World CD30 (TNFRSF8) Antibody Production by Region (2023-2028) & (K Units)
Table 8. World CD30 (TNFRSF8) Antibody Production Market Share by Region (2017-2022)
Table 9. World CD30 (TNFRSF8) Antibody Production Market Share by Region (2023-2028)
Table 10. World CD30 (TNFRSF8) Antibody Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World CD30 (TNFRSF8) Antibody Average Price by Region (2023-2028) & (US$/Unit)
Table 12. CD30 (TNFRSF8) Antibody Major Market Trends
Table 13. World CD30 (TNFRSF8) Antibody Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World CD30 (TNFRSF8) Antibody Consumption by Region (2017-2022) & (K Units)
Table 15. World CD30 (TNFRSF8) Antibody Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World CD30 (TNFRSF8) Antibody Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key CD30 (TNFRSF8) Antibody Producers in 2021
Table 18. World CD30 (TNFRSF8) Antibody Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key CD30 (TNFRSF8) Antibody Producers in 2021
Table 20. World CD30 (TNFRSF8) Antibody Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global CD30 (TNFRSF8) Antibody Company Evaluation Quadrant
Table 22. World CD30 (TNFRSF8) Antibody Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and CD30 (TNFRSF8) Antibody Production Site of Key Manufacturer
Table 24. CD30 (TNFRSF8) Antibody Market: Company Product Type Footprint
Table 25. CD30 (TNFRSF8) Antibody Market: Company Product Application Footprint
Table 26. CD30 (TNFRSF8) Antibody Competitive Factors
Table 27. CD30 (TNFRSF8) Antibody New Entrant and Capacity Expansion Plans
Table 28. CD30 (TNFRSF8) Antibody Mergers & Acquisitions Activity
Table 29. United States VS China CD30 (TNFRSF8) Antibody Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China CD30 (TNFRSF8) Antibody Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China CD30 (TNFRSF8) Antibody Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of CD30 (TNFRSF8) Antibody in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States CD30 (TNFRSF8) Antibody Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States CD30 (TNFRSF8) Antibody Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of CD30 (TNFRSF8) Antibody in China, Company Headquarters and Production Place (Province, Country)
Table 38. China CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China CD30 (TNFRSF8) Antibody Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China CD30 (TNFRSF8) Antibody Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of CD30 (TNFRSF8) Antibody in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World CD30 (TNFRSF8) Antibody Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World CD30 (TNFRSF8) Antibody Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World CD30 (TNFRSF8) Antibody Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World CD30 (TNFRSF8) Antibody Production by Type (2017-2022) & (K Units)
Table 49. World CD30 (TNFRSF8) Antibody Production by Type (2023-2028) & (K Units)
Table 50. World CD30 (TNFRSF8) Antibody Production Value by Type (2017-2022) & (USD Million)
Table 51. World CD30 (TNFRSF8) Antibody Production Value by Type (2023-2028) & (USD Million)
Table 52. World CD30 (TNFRSF8) Antibody Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World CD30 (TNFRSF8) Antibody Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World CD30 (TNFRSF8) Antibody Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World CD30 (TNFRSF8) Antibody Production by Application (2017-2022) & (K Units)
Table 56. World CD30 (TNFRSF8) Antibody Production by Application (2023-2028) & (K Units)
Table 57. World CD30 (TNFRSF8) Antibody Production Value by Application (2017-2022) & (USD Million)
Table 58. World CD30 (TNFRSF8) Antibody Production Value by Application (2023-2028) & (USD Million)
Table 59. World CD30 (TNFRSF8) Antibody Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World CD30 (TNFRSF8) Antibody Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Sino Biological, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Sino Biological, Inc. Major Business
Table 63. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 64. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Sino Biological, Inc. Recent Developments/Updates
Table 66. Sino Biological, Inc. Competitive Strengths & Weaknesses
Table 67. Bio-Techne Basic Information, Manufacturing Base and Competitors
Table 68. Bio-Techne Major Business
Table 69. Bio-Techne CD30 (TNFRSF8) Antibody Product and Services
Table 70. Bio-Techne CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Bio-Techne Recent Developments/Updates
Table 72. Bio-Techne Competitive Strengths & Weaknesses
Table 73. Thermo Fisher Scientific (China) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 74. Thermo Fisher Scientific (China) Co., Ltd. Major Business
Table 75. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product and Services
Table 76. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
Table 78. Thermo Fisher Scientific (China) Co., Ltd. Competitive Strengths & Weaknesses
Table 79. Boster Biological Technology Basic Information, Manufacturing Base and Competitors
Table 80. Boster Biological Technology Major Business
Table 81. Boster Biological Technology CD30 (TNFRSF8) Antibody Product and Services
Table 82. Boster Biological Technology CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Boster Biological Technology Recent Developments/Updates
Table 84. Boster Biological Technology Competitive Strengths & Weaknesses
Table 85. MyBiosource, Inc. Basic Information, Manufacturing Base and Competitors
Table 86. MyBiosource, Inc. Major Business
Table 87. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 88. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. MyBiosource, Inc. Recent Developments/Updates
Table 90. MyBiosource, Inc. Competitive Strengths & Weaknesses
Table 91. Abeomics Inc. Basic Information, Manufacturing Base and Competitors
Table 92. Abeomics Inc. Major Business
Table 93. Abeomics Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 94. Abeomics Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. Abeomics Inc. Recent Developments/Updates
Table 96. Abeomics Inc. Competitive Strengths & Weaknesses
Table 97. Abbexa Basic Information, Manufacturing Base and Competitors
Table 98. Abbexa Major Business
Table 99. Abbexa CD30 (TNFRSF8) Antibody Product and Services
Table 100. Abbexa CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Abbexa Recent Developments/Updates
Table 102. Abbexa Competitive Strengths & Weaknesses
Table 103. Cell Signaling Technology, Inc. Basic Information, Manufacturing Base and Competitors
Table 104. Cell Signaling Technology, Inc. Major Business
Table 105. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 106. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. Cell Signaling Technology, Inc. Recent Developments/Updates
Table 108. Cell Signaling Technology, Inc. Competitive Strengths & Weaknesses
Table 109. Creative Diagnostics Basic Information, Manufacturing Base and Competitors
Table 110. Creative Diagnostics Major Business
Table 111. Creative Diagnostics CD30 (TNFRSF8) Antibody Product and Services
Table 112. Creative Diagnostics CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Creative Diagnostics Recent Developments/Updates
Table 114. Creative Diagnostics Competitive Strengths & Weaknesses
Table 115. OriGene Technologies, Inc. Basic Information, Manufacturing Base and Competitors
Table 116. OriGene Technologies, Inc. Major Business
Table 117. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 118. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 119. OriGene Technologies, Inc. Recent Developments/Updates
Table 120. OriGene Technologies, Inc. Competitive Strengths & Weaknesses
Table 121. Merck Basic Information, Manufacturing Base and Competitors
Table 122. Merck Major Business
Table 123. Merck CD30 (TNFRSF8) Antibody Product and Services
Table 124. Merck CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 125. Merck Recent Developments/Updates
Table 126. Merck Competitive Strengths & Weaknesses
Table 127. Cayman Chemical Basic Information, Manufacturing Base and Competitors
Table 128. Cayman Chemical Major Business
Table 129. Cayman Chemical CD30 (TNFRSF8) Antibody Product and Services
Table 130. Cayman Chemical CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 131. Cayman Chemical Recent Developments/Updates
Table 132. Cayman Chemical Competitive Strengths & Weaknesses
Table 133. CUSABIO Basic Information, Manufacturing Base and Competitors
Table 134. CUSABIO Major Business
Table 135. CUSABIO CD30 (TNFRSF8) Antibody Product and Services
Table 136. CUSABIO CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 137. CUSABIO Recent Developments/Updates
Table 138. CUSABIO Competitive Strengths & Weaknesses
Table 139. Biotium Basic Information, Manufacturing Base and Competitors
Table 140. Biotium Major Business
Table 141. Biotium CD30 (TNFRSF8) Antibody Product and Services
Table 142. Biotium CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 143. Biotium Recent Developments/Updates
Table 144. Biotium Competitive Strengths & Weaknesses
Table 145. BioLegend Basic Information, Manufacturing Base and Competitors
Table 146. BioLegend Major Business
Table 147. BioLegend CD30 (TNFRSF8) Antibody Product and Services
Table 148. BioLegend CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 149. BioLegend Recent Developments/Updates
Table 150. BioLegend Competitive Strengths & Weaknesses
Table 151. Abcepta Basic Information, Manufacturing Base and Competitors
Table 152. Abcepta Major Business
Table 153. Abcepta CD30 (TNFRSF8) Antibody Product and Services
Table 154. Abcepta CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 155. Abcepta Recent Developments/Updates
Table 156. ProSci Incorporated Basic Information, Manufacturing Base and Competitors
Table 157. ProSci Incorporated Major Business
Table 158. ProSci Incorporated CD30 (TNFRSF8) Antibody Product and Services
Table 159. ProSci Incorporated CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 160. CD30 (TNFRSF8) Antibody Raw Material
Table 161. Key Manufacturers of CD30 (TNFRSF8) Antibody Raw Materials
Table 162. CD30 (TNFRSF8) Antibody Typical Distributors
Table 163. CD30 (TNFRSF8) Antibody Typical Customers
Table 1. World CD30 (TNFRSF8) Antibody Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World CD30 (TNFRSF8) Antibody Production Value by Region (2017-2022) & (USD Million)
Table 3. World CD30 (TNFRSF8) Antibody Production Value by Region (2023-2028) & (USD Million)
Table 4. World CD30 (TNFRSF8) Antibody Production Value Market Share by Region (2017-2022)
Table 5. World CD30 (TNFRSF8) Antibody Production Value Market Share by Region (2023-2028)
Table 6. World CD30 (TNFRSF8) Antibody Production by Region (2017-2022) & (K Units)
Table 7. World CD30 (TNFRSF8) Antibody Production by Region (2023-2028) & (K Units)
Table 8. World CD30 (TNFRSF8) Antibody Production Market Share by Region (2017-2022)
Table 9. World CD30 (TNFRSF8) Antibody Production Market Share by Region (2023-2028)
Table 10. World CD30 (TNFRSF8) Antibody Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World CD30 (TNFRSF8) Antibody Average Price by Region (2023-2028) & (US$/Unit)
Table 12. CD30 (TNFRSF8) Antibody Major Market Trends
Table 13. World CD30 (TNFRSF8) Antibody Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World CD30 (TNFRSF8) Antibody Consumption by Region (2017-2022) & (K Units)
Table 15. World CD30 (TNFRSF8) Antibody Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World CD30 (TNFRSF8) Antibody Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key CD30 (TNFRSF8) Antibody Producers in 2021
Table 18. World CD30 (TNFRSF8) Antibody Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key CD30 (TNFRSF8) Antibody Producers in 2021
Table 20. World CD30 (TNFRSF8) Antibody Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global CD30 (TNFRSF8) Antibody Company Evaluation Quadrant
Table 22. World CD30 (TNFRSF8) Antibody Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and CD30 (TNFRSF8) Antibody Production Site of Key Manufacturer
Table 24. CD30 (TNFRSF8) Antibody Market: Company Product Type Footprint
Table 25. CD30 (TNFRSF8) Antibody Market: Company Product Application Footprint
Table 26. CD30 (TNFRSF8) Antibody Competitive Factors
Table 27. CD30 (TNFRSF8) Antibody New Entrant and Capacity Expansion Plans
Table 28. CD30 (TNFRSF8) Antibody Mergers & Acquisitions Activity
Table 29. United States VS China CD30 (TNFRSF8) Antibody Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China CD30 (TNFRSF8) Antibody Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China CD30 (TNFRSF8) Antibody Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of CD30 (TNFRSF8) Antibody in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States CD30 (TNFRSF8) Antibody Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States CD30 (TNFRSF8) Antibody Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of CD30 (TNFRSF8) Antibody in China, Company Headquarters and Production Place (Province, Country)
Table 38. China CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China CD30 (TNFRSF8) Antibody Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China CD30 (TNFRSF8) Antibody Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of CD30 (TNFRSF8) Antibody in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World CD30 (TNFRSF8) Antibody Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World CD30 (TNFRSF8) Antibody Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World CD30 (TNFRSF8) Antibody Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World CD30 (TNFRSF8) Antibody Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World CD30 (TNFRSF8) Antibody Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World CD30 (TNFRSF8) Antibody Production by Type (2017-2022) & (K Units)
Table 49. World CD30 (TNFRSF8) Antibody Production by Type (2023-2028) & (K Units)
Table 50. World CD30 (TNFRSF8) Antibody Production Value by Type (2017-2022) & (USD Million)
Table 51. World CD30 (TNFRSF8) Antibody Production Value by Type (2023-2028) & (USD Million)
Table 52. World CD30 (TNFRSF8) Antibody Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World CD30 (TNFRSF8) Antibody Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World CD30 (TNFRSF8) Antibody Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World CD30 (TNFRSF8) Antibody Production by Application (2017-2022) & (K Units)
Table 56. World CD30 (TNFRSF8) Antibody Production by Application (2023-2028) & (K Units)
Table 57. World CD30 (TNFRSF8) Antibody Production Value by Application (2017-2022) & (USD Million)
Table 58. World CD30 (TNFRSF8) Antibody Production Value by Application (2023-2028) & (USD Million)
Table 59. World CD30 (TNFRSF8) Antibody Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World CD30 (TNFRSF8) Antibody Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Sino Biological, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Sino Biological, Inc. Major Business
Table 63. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 64. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Sino Biological, Inc. Recent Developments/Updates
Table 66. Sino Biological, Inc. Competitive Strengths & Weaknesses
Table 67. Bio-Techne Basic Information, Manufacturing Base and Competitors
Table 68. Bio-Techne Major Business
Table 69. Bio-Techne CD30 (TNFRSF8) Antibody Product and Services
Table 70. Bio-Techne CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Bio-Techne Recent Developments/Updates
Table 72. Bio-Techne Competitive Strengths & Weaknesses
Table 73. Thermo Fisher Scientific (China) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 74. Thermo Fisher Scientific (China) Co., Ltd. Major Business
Table 75. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product and Services
Table 76. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
Table 78. Thermo Fisher Scientific (China) Co., Ltd. Competitive Strengths & Weaknesses
Table 79. Boster Biological Technology Basic Information, Manufacturing Base and Competitors
Table 80. Boster Biological Technology Major Business
Table 81. Boster Biological Technology CD30 (TNFRSF8) Antibody Product and Services
Table 82. Boster Biological Technology CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Boster Biological Technology Recent Developments/Updates
Table 84. Boster Biological Technology Competitive Strengths & Weaknesses
Table 85. MyBiosource, Inc. Basic Information, Manufacturing Base and Competitors
Table 86. MyBiosource, Inc. Major Business
Table 87. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 88. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. MyBiosource, Inc. Recent Developments/Updates
Table 90. MyBiosource, Inc. Competitive Strengths & Weaknesses
Table 91. Abeomics Inc. Basic Information, Manufacturing Base and Competitors
Table 92. Abeomics Inc. Major Business
Table 93. Abeomics Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 94. Abeomics Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. Abeomics Inc. Recent Developments/Updates
Table 96. Abeomics Inc. Competitive Strengths & Weaknesses
Table 97. Abbexa Basic Information, Manufacturing Base and Competitors
Table 98. Abbexa Major Business
Table 99. Abbexa CD30 (TNFRSF8) Antibody Product and Services
Table 100. Abbexa CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Abbexa Recent Developments/Updates
Table 102. Abbexa Competitive Strengths & Weaknesses
Table 103. Cell Signaling Technology, Inc. Basic Information, Manufacturing Base and Competitors
Table 104. Cell Signaling Technology, Inc. Major Business
Table 105. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 106. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. Cell Signaling Technology, Inc. Recent Developments/Updates
Table 108. Cell Signaling Technology, Inc. Competitive Strengths & Weaknesses
Table 109. Creative Diagnostics Basic Information, Manufacturing Base and Competitors
Table 110. Creative Diagnostics Major Business
Table 111. Creative Diagnostics CD30 (TNFRSF8) Antibody Product and Services
Table 112. Creative Diagnostics CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Creative Diagnostics Recent Developments/Updates
Table 114. Creative Diagnostics Competitive Strengths & Weaknesses
Table 115. OriGene Technologies, Inc. Basic Information, Manufacturing Base and Competitors
Table 116. OriGene Technologies, Inc. Major Business
Table 117. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product and Services
Table 118. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 119. OriGene Technologies, Inc. Recent Developments/Updates
Table 120. OriGene Technologies, Inc. Competitive Strengths & Weaknesses
Table 121. Merck Basic Information, Manufacturing Base and Competitors
Table 122. Merck Major Business
Table 123. Merck CD30 (TNFRSF8) Antibody Product and Services
Table 124. Merck CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 125. Merck Recent Developments/Updates
Table 126. Merck Competitive Strengths & Weaknesses
Table 127. Cayman Chemical Basic Information, Manufacturing Base and Competitors
Table 128. Cayman Chemical Major Business
Table 129. Cayman Chemical CD30 (TNFRSF8) Antibody Product and Services
Table 130. Cayman Chemical CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 131. Cayman Chemical Recent Developments/Updates
Table 132. Cayman Chemical Competitive Strengths & Weaknesses
Table 133. CUSABIO Basic Information, Manufacturing Base and Competitors
Table 134. CUSABIO Major Business
Table 135. CUSABIO CD30 (TNFRSF8) Antibody Product and Services
Table 136. CUSABIO CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 137. CUSABIO Recent Developments/Updates
Table 138. CUSABIO Competitive Strengths & Weaknesses
Table 139. Biotium Basic Information, Manufacturing Base and Competitors
Table 140. Biotium Major Business
Table 141. Biotium CD30 (TNFRSF8) Antibody Product and Services
Table 142. Biotium CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 143. Biotium Recent Developments/Updates
Table 144. Biotium Competitive Strengths & Weaknesses
Table 145. BioLegend Basic Information, Manufacturing Base and Competitors
Table 146. BioLegend Major Business
Table 147. BioLegend CD30 (TNFRSF8) Antibody Product and Services
Table 148. BioLegend CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 149. BioLegend Recent Developments/Updates
Table 150. BioLegend Competitive Strengths & Weaknesses
Table 151. Abcepta Basic Information, Manufacturing Base and Competitors
Table 152. Abcepta Major Business
Table 153. Abcepta CD30 (TNFRSF8) Antibody Product and Services
Table 154. Abcepta CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 155. Abcepta Recent Developments/Updates
Table 156. ProSci Incorporated Basic Information, Manufacturing Base and Competitors
Table 157. ProSci Incorporated Major Business
Table 158. ProSci Incorporated CD30 (TNFRSF8) Antibody Product and Services
Table 159. ProSci Incorporated CD30 (TNFRSF8) Antibody Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 160. CD30 (TNFRSF8) Antibody Raw Material
Table 161. Key Manufacturers of CD30 (TNFRSF8) Antibody Raw Materials
Table 162. CD30 (TNFRSF8) Antibody Typical Distributors
Table 163. CD30 (TNFRSF8) Antibody Typical Customers
LIST OF FIGURES
Figure 1. CD30 (TNFRSF8) Antibody Picture
Figure 2. World CD30 (TNFRSF8) Antibody Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World CD30 (TNFRSF8) Antibody Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 5. World CD30 (TNFRSF8) Antibody Average Price (2017-2028) & (US$/Unit)
Figure 6. World CD30 (TNFRSF8) Antibody Production Value Market Share by Region (2017-2028)
Figure 7. World CD30 (TNFRSF8) Antibody Production Market Share by Region (2017-2028)
Figure 8. North America CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 9. Europe CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 10. China CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 11. Japan CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 12. CD30 (TNFRSF8) Antibody Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World CD30 (TNFRSF8) Antibody Demand (2017-2028) & (K Units)
Figure 15. World CD30 (TNFRSF8) Antibody Consumption Market Share by Region (2017-2028)
Figure 16. United States CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 17. China CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 18. Europe CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 19. Japan CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 20. South Korea CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 21. ASEAN CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 22. India CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of CD30 (TNFRSF8) Antibody by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for CD30 (TNFRSF8) Antibody Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for CD30 (TNFRSF8) Antibody Markets in 2021
Figure 26. United States VS China: CD30 (TNFRSF8) Antibody Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: CD30 (TNFRSF8) Antibody Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: CD30 (TNFRSF8) Antibody Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of CD30 (TNFRSF8) Antibody in United States
Figure 30. Key Producers and Market Share of CD30 (TNFRSF8) Antibody in China
Figure 31. Key Producers and Market Share of CD30 (TNFRSF8) Antibody in Rest of World
Figure 32. World CD30 (TNFRSF8) Antibody Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World CD30 (TNFRSF8) Antibody Production Value Market Share by Type in 2021
Figure 34. Monoclonal Antibody
Figure 35. Polyclonal Antibody
Figure 36. World CD30 (TNFRSF8) Antibody Production Market Share by Type (2017-2028)
Figure 37. World CD30 (TNFRSF8) Antibody Production Value Market Share by Type (2017-2028)
Figure 38. World CD30 (TNFRSF8) Antibody Average Price by Type (2017-2028) & (US$/Unit)
Figure 39. World CD30 (TNFRSF8) Antibody Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 40. World CD30 (TNFRSF8) Antibody Production Value Market Share by Application in 2021
Figure 41. Flow Cytometry
Figure 42. ELISA
Figure 43. Western Blot
Figure 44. Immunofluorescence
Figure 45. Other
Figure 46. World CD30 (TNFRSF8) Antibody Production Market Share by Application (2017-2028)
Figure 47. World CD30 (TNFRSF8) Antibody Production Value Market Share by Application (2017-2028)
Figure 48. World CD30 (TNFRSF8) Antibody Average Price by Application (2017-2028) & (US$/Unit)
Figure 49. Manufacturing Cost Structure Analysis of CD30 (TNFRSF8) Antibody in 2021
Figure 50. Manufacturing Process Analysis of CD30 (TNFRSF8) Antibody
Figure 51. CD30 (TNFRSF8) Antibody Industrial Chain
Figure 52. Distribution Channel Breakdown for CD30 (TNFRSF8) Antibody Shipments (%): 2017-2028
Figure 53. Direct Channel Pros & Cons
Figure 54. Indirect Channel Pros & Cons
Figure 55. Methodology
Figure 56. Research Process and Data Source
Figure 1. CD30 (TNFRSF8) Antibody Picture
Figure 2. World CD30 (TNFRSF8) Antibody Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World CD30 (TNFRSF8) Antibody Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 5. World CD30 (TNFRSF8) Antibody Average Price (2017-2028) & (US$/Unit)
Figure 6. World CD30 (TNFRSF8) Antibody Production Value Market Share by Region (2017-2028)
Figure 7. World CD30 (TNFRSF8) Antibody Production Market Share by Region (2017-2028)
Figure 8. North America CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 9. Europe CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 10. China CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 11. Japan CD30 (TNFRSF8) Antibody Production (2017-2028) & (K Units)
Figure 12. CD30 (TNFRSF8) Antibody Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World CD30 (TNFRSF8) Antibody Demand (2017-2028) & (K Units)
Figure 15. World CD30 (TNFRSF8) Antibody Consumption Market Share by Region (2017-2028)
Figure 16. United States CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 17. China CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 18. Europe CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 19. Japan CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 20. South Korea CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 21. ASEAN CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 22. India CD30 (TNFRSF8) Antibody Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of CD30 (TNFRSF8) Antibody by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for CD30 (TNFRSF8) Antibody Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for CD30 (TNFRSF8) Antibody Markets in 2021
Figure 26. United States VS China: CD30 (TNFRSF8) Antibody Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: CD30 (TNFRSF8) Antibody Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: CD30 (TNFRSF8) Antibody Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of CD30 (TNFRSF8) Antibody in United States
Figure 30. Key Producers and Market Share of CD30 (TNFRSF8) Antibody in China
Figure 31. Key Producers and Market Share of CD30 (TNFRSF8) Antibody in Rest of World
Figure 32. World CD30 (TNFRSF8) Antibody Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World CD30 (TNFRSF8) Antibody Production Value Market Share by Type in 2021
Figure 34. Monoclonal Antibody
Figure 35. Polyclonal Antibody
Figure 36. World CD30 (TNFRSF8) Antibody Production Market Share by Type (2017-2028)
Figure 37. World CD30 (TNFRSF8) Antibody Production Value Market Share by Type (2017-2028)
Figure 38. World CD30 (TNFRSF8) Antibody Average Price by Type (2017-2028) & (US$/Unit)
Figure 39. World CD30 (TNFRSF8) Antibody Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 40. World CD30 (TNFRSF8) Antibody Production Value Market Share by Application in 2021
Figure 41. Flow Cytometry
Figure 42. ELISA
Figure 43. Western Blot
Figure 44. Immunofluorescence
Figure 45. Other
Figure 46. World CD30 (TNFRSF8) Antibody Production Market Share by Application (2017-2028)
Figure 47. World CD30 (TNFRSF8) Antibody Production Value Market Share by Application (2017-2028)
Figure 48. World CD30 (TNFRSF8) Antibody Average Price by Application (2017-2028) & (US$/Unit)
Figure 49. Manufacturing Cost Structure Analysis of CD30 (TNFRSF8) Antibody in 2021
Figure 50. Manufacturing Process Analysis of CD30 (TNFRSF8) Antibody
Figure 51. CD30 (TNFRSF8) Antibody Industrial Chain
Figure 52. Distribution Channel Breakdown for CD30 (TNFRSF8) Antibody Shipments (%): 2017-2028
Figure 53. Direct Channel Pros & Cons
Figure 54. Indirect Channel Pros & Cons
Figure 55. Methodology
Figure 56. Research Process and Data Source
